For the first time, researchers could watch cells transition from benign to malignant
In a Barcelona laboratory, scientists have done what living patients could not easily offer: a clear window into the moment a harmless nerve tumor becomes something far more dangerous. By reprogramming ordinary cells to carry the genetic signatures of neurofibromatosis type 1, researchers at the Germans Trias i Pujol Research Institute have mapped the molecular turning point of malignant transformation — and found, waiting there, a vulnerability that two existing drugs may be able to exploit. It is a reminder that understanding how illness unfolds is often the first, most necessary step toward interrupting it.
- Malignant peripheral nerve sheath tumors carry a grim prognosis, and until now no reliable laboratory model existed to study how they arise from benign NF1 growths.
- The loss of a single protein complex — PRC2 — triggers a sweeping reorganization of genetic activity that effectively reprograms cells toward aggressive malignancy.
- Researchers engineered stem cells to carry NF1 mutations in sequence, allowing them to watch the transformation unfold step by step in a petri dish for the first time.
- Screening hundreds of compounds against this newly understood vulnerability, the team identified PARP inhibitors as a promising class of drugs for PRC2-deficient tumors.
- The combination of olaparib and selumetinib produced significant tumor reduction in preclinical models, pointing toward a clinical trial pathway for a cancer with historically few options.
Scientists at the Germans Trias i Pujol Research Institute, working alongside collaborators at the U.S. National Institutes of Health, have built the first laboratory model capable of capturing how neurofibromatosis type 1 tumors cross the threshold from benign to malignant. The findings, published in Nature Communications, offer both a new understanding of the disease and a concrete lead for treatment.
Neurofibromatosis type 1 is a genetic condition that causes tumors to grow along peripheral nerves. Most remain harmless across a patient's lifetime, but a subset transform into malignant peripheral nerve sheath tumors — an aggressive sarcoma with few effective treatments. Because this progression is difficult to observe in living patients, its molecular causes have long remained obscure.
The team addressed this by engineering induced pluripotent stem cells — adult cells rewound to an embryonic state — to carry NF1 mutations introduced one by one. Watching cells move through successive stages of malignancy in a dish, they identified a critical driver: the loss of the PRC2 protein complex. Normally, PRC2 governs which genes are active through epigenetic regulation. When it disappears, cells undergo a sweeping reorganization of genetic activity that confers the hallmarks of cancer — not randomly, but along a recognizable path.
Armed with this mechanism, the researchers screened hundreds of compounds and found that PRC2-deficient tumors are unusually sensitive to PARP inhibitors, a drug class already established in breast cancer treatment. Combining olaparib, a PARP inhibitor, with selumetinib — which targets a separate cancer-driving pathway — produced striking tumor reduction in preclinical models.
Beyond the drug combination itself, the team has created a reusable platform for testing future therapies against NF1 tumors. For patients facing a historically grim diagnosis, the path to clinical trials is now built on a far clearer scientific foundation.
Scientists at the Germans Trias i Pujol Research Institute have built the first laboratory model that captures how neurofibromatosis type 1 tumors transform from harmless growths into aggressive cancers. The breakthrough, published in Nature Communications, emerged from a collaboration spanning Barcelona and the U.S. National Institutes of Health, and it points toward a potential treatment combining two existing drugs.
Neurofibromatosis type 1 is a genetic condition that predisposes people to develop tumors along their peripheral nerves. Most remain benign throughout a person's life. But some progress to malignant peripheral nerve sheath tumors—a particularly vicious form of sarcoma that offers patients few effective options. Understanding why this transformation happens, and how to stop it, has remained elusive because the disease's progression is difficult to study in living patients.
The research team solved this by engineering induced pluripotent stem cells—ordinary adult cells reprogrammed to an embryonic state—to carry the genetic mutations that drive NF1 disease. By introducing these mutations sequentially, they could watch cells transition from a benign state to increasingly malignant stages, all within a petri dish. For the first time, researchers could observe the precise molecular choreography of this transformation with clarity impossible in human tissue.
The work revealed that loss of the PRC2 complex acts as a critical switch. This protein complex normally regulates which genes are turned on and off through epigenetic mechanisms—chemical modifications that don't alter DNA itself but profoundly affect how cells behave. When PRC2 disappears, the researchers found, cells undergo a global reorganization of genetic activity that equips them with hallmarks of malignancy. The transformation isn't random; it follows a recognizable path.
Once they understood this mechanism, the team screened hundreds of compounds to find which ones could exploit this vulnerability. They discovered that tumors lacking PRC2 show particular sensitivity to PARP inhibitors—a class of drugs already used against certain breast cancers. When they combined olaparib, a PARP inhibitor, with selumetinib, a drug that blocks a different cancer-driving pathway, the effect was striking: tumor growth dropped significantly in preclinical models.
The significance lies not just in identifying a drug combination, but in creating a platform that can be used repeatedly. Researchers can now test other compounds against NF1 tumors in ways that were previously impossible. For patients with malignant peripheral nerve sheath tumors, a diagnosis that has historically offered grim prospects and limited treatments, this opens a tangible new direction. The next step is moving from laboratory success to clinical trials, a process that typically takes years but now has a clearer scientific foundation.
Citas Notables
This helps us better understand the mechanisms driving this transformation and provides us with a new platform to identify potential therapeutic strategies— Meritxell Carrió, co-senior author
The results obtained with the combination of olaparib and selumetinib open up new avenues of research in tumors that currently have very few treatment options— Eduard Serra, IGTP researcher
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that they built this in a dish rather than studying the disease in patients?
Because you can't watch transformation happen in a person—it takes years, and you can't biopsy at every stage. In the lab, they controlled exactly which mutations appeared and when, so they could see the precise moment cells became malignant.
What does PRC2 actually do?
It's like a librarian that decides which books stay on the shelf and which get archived. When it's gone, the cell's entire library of active genes gets reshuffled, and suddenly the cell has all the traits of a cancer cell.
Why would a PARP inhibitor work here when it's used for breast cancer?
Because the vulnerability isn't unique to breast cancer—it's a weakness in any cell that's lost PRC2. The researchers found that these NF1 tumors have that same weakness, so the same drug that exploits it in one cancer might work in another.
Is this treatment ready for patients now?
Not yet. They've shown it works in preclinical models—essentially sophisticated lab experiments. Clinical trials would come next, which takes time. But they've given oncologists a specific target and a specific drug combination to test.
What happens to patients right now, before trials begin?
They still have very few options. That's why this work matters—it's the first real scientific pathway toward something better for a disease that's been largely untreatable once it turns malignant.